

16 September 2016

October 2016 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **October 2016** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Cetirizine hydrochloride (Zista) tab 10 mg (p'code 2500728)
- Cilazapril (Apo-Cilazapril) tab 2.5 mg (p'code 2499711) and 5 mg (p'code 2499738)
- Oral feed (powder) (Ensure) powder (chocolate), 850 g OP – Special Authority – Hospital pharmacy [HP3], new formulation (p'code 2504324)
- Pantoprazole (Panzop Relief) tab EC 20 mg (p'code 2496216) and EC 40 mg (p'code 2496224)

Changes to restrictions, chemical names and presentations

- Coal tar (Midwest) soln BP – amended presentation description
- Cinacalcet (Sensipar) tab 30 mg – amended Special Authority criteria
- Fludarabine phosphate (Fludarabine Ebewe and Fludara) inj 50 mg vial – amended presentation description
- Goserelin (Zoladex) implant 3.6 mg, syringe and implant 10.8 mg, syringe – amended chemical name and presentation description
- Hormone replacement therapy - systemic – Special Authority removed
- Ipratropium bromide (Univent) nebuliser soln, 250 mcg per ml, 1 ml and 2 ml ampoules – amended presentation description
- Leuprorelin (Lucrin and Eligard) various presentations – amended presentation descriptions and brand names
- Oestradiol TDDS 3.9 mg (releases 50 mcg of oestradiol per day) (Climara 50) and TDDS 7.8 mg (releases 100 mcg of oestradiol per day) (Climara 100) – Higher subsidy with Special Authority removed
- Pancreatic enzyme cap – amended presentation description
- Paritaprevir, ritonavir and ombitasvir with dasabuvir (Viekira Pak) tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56) – amended restriction
- Paritaprevir, ritonavir and ombitasvir with dasabuvir and ribavirin (Viekira Pak-RBV) tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56) with dasabuvir tab 250 mg (56) and ribavirin tab 200 mg (168) – amended restriction
- Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol) – Stat dispensing reinstated
- Section C: extemporaneously compounded products and galenicals, Introduction – amended restriction

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Aspirin	Tab 100 mg Tab dispersible 300 mg	Ethics Aspirin EC Ethics Aspirin
Coal tar	Soln BP, 200 ml	Midwest
Compound electrolytes	Powder for oral soln	Enerlyte
Hydrocortisone	Crn 1%, 500 g	Pharmacy Health
Ipratropium bromide	Nebuliser soln, 250 mcg per ml, 1 ml and 2 ml ampoules	Univent
Selegiline hydrochloride	Tab 5 mg	Apo-Selegiline S29

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Aciclovir	Eye oint 3%, 4.5 g OP	ViruPOS*	Zovirax
Amiodarone hydrochloride	Tab 100 mg	Cordarone-X*	Aratac
	Tab 200 mg	Aratac Cordarone-X*	
Goserelin	Implant syringe 3.6 mg & 10.8 mg	Zoladex	

* no subsidy changes for these brands for 1 October 2016.

Do you prefer email communications?

We have received feedback from pharmacists that they would prefer communications from us via email. If you would like to receive future updates by email, please provide **your email address** to us at enquiry@pharmac.govt.nz. Please put "email or fax preference" in the subject line.

If email is not an option for you, and you would like to continue to receive faxed communications from us, please let us know that too.